Novartis’ Cosentyx (secukinumab) Receives the US FDA’s Approval as First Intravenous Formulation for Rheumatic Diseases
Shots:
- The US FDA has approved an IV formulation of Cosentyx (secukinumab) for the treatment of adults with PsA, AS, and non-radiographic axial spondyloarthritis (nr-axSpA). The new IV administration option will be available in Q4’23
- The therapy offers healthcare providers choice and flexibility to tailor treatment to their patient's unique needs & IV formulation of Cosentyx provides patients a monthly 30-minute, weight-based dosing option that does not require pre-medication and lab monitoring
- Cosentyx is a fully human biologic that specifically targets and blocks interleukin-17A (IL-17A). The therapy was approved in 100+ countries & was recently approved for JIA and hidradenitis suppurativa in the EU
Ref: Novartis| Image: Novartis
Related News:- Novartis Receives EMA’s CHMP Positive Opinion Recommending Marketing Authorization of Cosentyx (secukinumab) for Hidradenitis Suppurativa
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
